Articles tagged with Control Antibodies
A randomized clinical trial shows that semaglutide improves glycemic control and weight outcomes in individuals with schizophrenia. The study suggests using glucagon-like peptide-1 receptor agonists as an early intervention strategy to reduce cardiometabolic risk in this population.
Scientists at Osaka Prefecture University have identified specific parts of the dog allergen Can f 1 that can trigger an immune response in people. The researchers used X-ray crystallography to determine the structure of the protein and found several potential epitopes, or regions, that could be targeted by a vaccine.
Researchers investigated SARS-CoV-2 BNT162b2 mRNA vaccine response in cancer patients and healthy controls. The study found that the vaccine's antispike IgG antibody response wanes over time in patients on active anticancer treatment.
Researchers assessed maternal, neonatal SARS-CoV-2 viral load and transplacental antibody transfer in 127 pregnancies. The study found reduced transplacental transfer of anti-SARS-CoV-2 antibodies, indicating effective maternal control of the virus.
Scientists from the University of Rome Tor Vergata created a method to use antibodies to control chemical reactions forming therapeutic agents and imaging molecules. The approach involves modifying synthetic DNA oligonucleotides with recognition elements targeting specific antibodies.
Scientists discovered human monoclonal antibodies specific to HBV surface antigens in natural controllers, which showed neutralizing ability and capabilities of blocking viral infection. The findings highlight a promising therapeutic tool for treating chronic HBV infection and may provide an alternative to existing treatments.
Researchers found that monkeys suppressed HIV-like virus SHIV after receiving dual-antibody treatment, which enabled their immune systems to control the virus long after the antibodies were gone. The study suggests a potential approach to treating HIV and other infections.
Researchers developed a blood test to assess human exposure to Aedes mosquitoes by measuring antibodies against one individual peptide from Aedes saliva. The test showed decreased human exposure to mosquito bites after a vector control program, with 88% of people having a positive antibody reaction before the intervention.
Researchers at Yale University have found a way for antibodies to enter the nervous system, allowing them to control viral infections. This discovery may lead to new treatments for conditions such as herpes and Guillain-Barre syndrome.
Researchers found that treatment with omalizumab significantly decreases the number of colds in inner-city children with allergic asthma. Omalizumab targets and reduces levels of immunoglobulin E, a key player in protecting against viruses like those causing cold symptoms.
Researchers from the University of Chicago have developed a novel approach to control enzyme activity using monobodies, synthetic proteins that recognize and bind specific target molecules. They successfully altered the specificity of an enzyme used in the food industry without modifying it, paving the way for bespoke reactions.
GlycoFi researchers have made a major leap in protein bioengineering by controlling sugar structures on antibodies to boost cancer-killing ability. This approach can be applied to any therapeutic glycoprotein, and the company is poised to capitalize on the growing 20% annual growth of the therapeutic protein market.